overall survival
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Meletios A Dimopoulos, Sagar Lonial, Wee-Joo Chng, Shinsuke Iida, María-Victoria Mateos, Gareth J Morgan, Cong Li, Catriona Byrne, Kaveri Suryanarayan, Richard Labotka, S Vincent Rajkumar
Blood Cancer J 16(1) 15
TOURMALINE-MM3 (NCT02181413) and -MM4 (NCT02312258) were phase 3 studies of fixed-duration, single-agent ixazomib maintenance in post-transplant (TOURMALINE-MM3)/transplant-ineligible (TOURMALINE-MM4) patients with newly diagnosed multiple myeloma (NDMM) that demonstrated improved median progression-free survival (PFS) for ixazomib vs placebo. We present the final overall survival (OS) analyses for each study separately. In both studies, eligible patients were randomized 3:2 to receive ixazomib maintenance (3 mg [cycles 1-4], 4 mg [from cycle 5 if tolerated]) or matching placebo for ≤26 cycles, or until progressive disease/unacceptable toxicity. At median follow-up of approximately 8 years (TOURMALINE-MM3) and 5 years (TOURMALINE-MM4), median OS was not reached in either arm in MM3 (hazard ratio [HR], 1.025; 95% confidence interval [CI], 0.789-1.332; p = 0.850), and was 64.8 (ixazomib) vs 69.5 (placebo) months in MM4 (HR, 1.090; 95% CI, 0.861-1.381; p = 0.473). No new safety signals were identified in either study; incidence of new primary malignancies was low. Despite meeting their primary endpoints (PFS), neither final OS analysis of TOURMALINE-MM3/-MM4 showed statistically significant differences between fixed-duration ixazomib maintenance and placebo in patients with NDMM. The growing number of available, highly effective salvage treatments with novel mechanisms of action make demonstrating an OS advantage in front-line myeloma studies increasingly challenging.
5 个 Figure · 10 个 KM 面板
Kaplan–Meier analysis of overall survival (ITT population). A TOURMALINE-MM3 study. B TOURMALINE-MM4 study. CI confidence interval, HR hazard ratio, NR not reached, OS overall survival.
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 · Panel B
Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Kaplan–Meier analysis of time to next treatment (ITT population). A TOURMALINE-MM3 study. B TOURMALINE-MM4 study. CI confidence interval, HR hazard ratio, ITT intention-to-treat, OS overall survival.
Fig. 4 · Panel A
Panel A 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel B
Panel B 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Progression-free survival in next-line therapy (ITT population). A TOURMALINE-MM3 study. B TOURMALINE MM4 study. CI confidence interval, HR hazard ratio, ITT intention-to-treat, OS overall survival.
Kaplan–Meier analysis of overall survival in patients who received a proteasome inhibitor as next-line therapy. A and TOURMALINE-MM3 study. B TOURMALINE-MM4 study. CI confidence interval, HR hazard ratio, OS overall survival.
Fig. 6 · Panel A
Panel A 是同一 Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 6 · Panel B
Panel B 是同一 Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Kaplan–Meier analysis of overall survival in patients whose next-line therapy did not include a proteasome inhibitor. A TOURMALINE-MM3 study. B TOURMALINE-MM4 study. CI confidence interval, HR hazard ratio, OS overall survival.
这些图片未产生 KM 曲线结果,不在主页面重复展示。